[
  {
    "ts": null,
    "headline": "Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials",
    "summary": "On Thursday, Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection. The trials included patients who were virologically suppressed on different antiretroviral therapy regimens, including antiretroviral therapy regimens [baseline antiretroviral therapy (bART) and Bictegravir/​Emtricitabine/​Tenofovir Alafenamide (BIC/​FTC/​TAF). DOR/ISL was demonstrated to be non-inferior to bART i",
    "url": "https://finnhub.io/api/news?id=81f10796f4612bf2472ea1b89c7dc574fc41d9a95dd535d741700734d69ecee6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734633566,
      "headline": "Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials",
      "id": 132060903,
      "image": "https://media.zenfs.com/en/Benzinga/c9cdceab5e92c621af8ad2411c3beb26",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "On Thursday, Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection. The trials included patients who were virologically suppressed on different antiretroviral therapy regimens, including antiretroviral therapy regimens [baseline antiretroviral therapy (bART) and Bictegravir/​Emtricitabine/​Tenofovir Alafenamide (BIC/​FTC/​TAF). DOR/ISL was demonstrated to be non-inferior to bART i",
      "url": "https://finnhub.io/api/news?id=81f10796f4612bf2472ea1b89c7dc574fc41d9a95dd535d741700734d69ecee6"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=e75eb93adfd95556fb84b660690a06fce9d51842627fa30f8364ba179a39810b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734626100,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 132065111,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=e75eb93adfd95556fb84b660690a06fce9d51842627fa30f8364ba179a39810b"
    }
  },
  {
    "ts": null,
    "headline": "A venture firm breathes new life into an old NGM drug",
    "summary": "An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare conditon.",
    "url": "https://finnhub.io/api/news?id=59461bf3412794cc943623de53a5839735779d978bbba9743a7840e42b0294e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734620400,
      "headline": "A venture firm breathes new life into an old NGM drug",
      "id": 132060904,
      "image": "https://imgproxy.divecdn.com/WBCrtQaKgp6ba9gWiasX6fgvopukoOkYcwR7CwSK06U/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTM5MDkwNTYwX0lGd2hlSmUuanBn.webp",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare conditon.",
      "url": "https://finnhub.io/api/news?id=59461bf3412794cc943623de53a5839735779d978bbba9743a7840e42b0294e5"
    }
  },
  {
    "ts": null,
    "headline": "Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug",
    "summary": "Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.",
    "url": "https://finnhub.io/api/news?id=083f981a62a40c54ded151168c5d691c3d7cbb33254b17ed0f73c178b267b55b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734614640,
      "headline": "Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug",
      "id": 132051883,
      "image": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.",
      "url": "https://finnhub.io/api/news?id=083f981a62a40c54ded151168c5d691c3d7cbb33254b17ed0f73c178b267b55b"
    }
  },
  {
    "ts": null,
    "headline": "MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset",
    "summary": "MSD could pursue “cardiometabolic benefits beyond weight reduction” for Hansoh’s weight loss pill.",
    "url": "https://finnhub.io/api/news?id=4010a2cdc1d33cbedcb79a819d6841074bb92963587fbcf82988f52a25da3510",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734611559,
      "headline": "MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset",
      "id": 132050485,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_1642618876-1.jpg",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MSD could pursue “cardiometabolic benefits beyond weight reduction” for Hansoh’s weight loss pill.",
      "url": "https://finnhub.io/api/news?id=4010a2cdc1d33cbedcb79a819d6841074bb92963587fbcf82988f52a25da3510"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Competition Fears Are Exaggerated",
    "summary": "Viking Therapeutics shows promise with weight loss drug VK2735 and potential in NASH treatment, making it a potential takeover target. Read more on VKTX here.",
    "url": "https://finnhub.io/api/news?id=f68f0ab502abbaa2855584a34573a73d3d30cef19848c50d38bb6cd463a08728",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734609342,
      "headline": "Viking Therapeutics: Competition Fears Are Exaggerated",
      "id": 132053590,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1719209231/image_1719209231.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics shows promise with weight loss drug VK2735 and potential in NASH treatment, making it a potential takeover target. Read more on VKTX here.",
      "url": "https://finnhub.io/api/news?id=f68f0ab502abbaa2855584a34573a73d3d30cef19848c50d38bb6cd463a08728"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection",
    "summary": "RAHWAY, N.J., December 19, 2024--Merck Announces Topline Results from Phase 3 Trials Evaluating Once-Daily, Oral Doravirine/Islatravir for the Treatment of Adults with HIV-1 Infection",
    "url": "https://finnhub.io/api/news?id=302a1e860c957a9931484dda1e60a331492ece8e638111164df8dfc7f6edb320",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734608700,
      "headline": "Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection",
      "id": 132050486,
      "image": "https://media.zenfs.com/en/business-wire.com/69d65fb3681f3bba63517484ef04504e",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 19, 2024--Merck Announces Topline Results from Phase 3 Trials Evaluating Once-Daily, Oral Doravirine/Islatravir for the Treatment of Adults with HIV-1 Infection",
      "url": "https://finnhub.io/api/news?id=302a1e860c957a9931484dda1e60a331492ece8e638111164df8dfc7f6edb320"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In?",
    "summary": "We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. Dividend-focused investors are often drawn to stocks with high yields, shaping their strategies around acquiring such […]",
    "url": "https://finnhub.io/api/news?id=b193de5fcb74686e54aec0ca10b70e97918ad747d6c36cba45607606b712d61a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734606756,
      "headline": "Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In?",
      "id": 132050487,
      "image": "https://s.yimg.com/ny/api/res/1.2/krpa0cobX2AdeFb7DJ59pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. Dividend-focused investors are often drawn to stocks with high yields, shaping their strategies around acquiring such […]",
      "url": "https://finnhub.io/api/news?id=b193de5fcb74686e54aec0ca10b70e97918ad747d6c36cba45607606b712d61a"
    }
  },
  {
    "ts": null,
    "headline": "Personalis Shares Surge After Merck's $50 Million Investment",
    "summary": "Personalis Shares Surge After Merck's $50 Million Investment",
    "url": "https://finnhub.io/api/news?id=07d40215c35d61b7d47ea1fe5d86c4263ee2af7f0e25aa6f53e1e4bef12b1175",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734605880,
      "headline": "Personalis Shares Surge After Merck's $50 Million Investment",
      "id": 132065112,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Personalis Shares Surge After Merck's $50 Million Investment",
      "url": "https://finnhub.io/api/news?id=07d40215c35d61b7d47ea1fe5d86c4263ee2af7f0e25aa6f53e1e4bef12b1175"
    }
  },
  {
    "ts": null,
    "headline": "Merck: encouraging phase III results in HIV",
    "summary": "On Thursday, Merck reported encouraging Phase III results for its experimental once-daily oral drug for HIV-1 patients.The US pharmaceutical giant reports that the combination of doravirine and...",
    "url": "https://finnhub.io/api/news?id=3aeef432e57113ef8d80cb4ea7230ebe6459937ee26ebcf0951a4c7afb5d9f33",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734602657,
      "headline": "Merck: encouraging phase III results in HIV",
      "id": 132051769,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "On Thursday, Merck reported encouraging Phase III results for its experimental once-daily oral drug for HIV-1 patients.The US pharmaceutical giant reports that the combination of doravirine and...",
      "url": "https://finnhub.io/api/news?id=3aeef432e57113ef8d80cb4ea7230ebe6459937ee26ebcf0951a4c7afb5d9f33"
    }
  },
  {
    "ts": null,
    "headline": "Merck Buys $50 Million of Personalis Stock",
    "summary": "By Dean Seal Personalis has received a $50 million equity investment from Merck and extended a deal for Moderna to use its platform and technology. The advanced cancer genomic testing...",
    "url": "https://finnhub.io/api/news?id=55d7b1f3cd6348974a258e51fd0e7f2ae37ed4819c31c576fd0d6a8a5abe2066",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734601573,
      "headline": "Merck Buys $50 Million of Personalis Stock",
      "id": 132051457,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Dean Seal Personalis has received a $50 million equity investment from Merck and extended a deal for Moderna to use its platform and technology. The advanced cancer genomic testing...",
      "url": "https://finnhub.io/api/news?id=55d7b1f3cd6348974a258e51fd0e7f2ae37ed4819c31c576fd0d6a8a5abe2066"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time",
    "summary": "Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my analysis of MRK stock.",
    "url": "https://finnhub.io/api/news?id=6449b500963559f7a1006b8cb1ae53370bba70ce91ce34311c71d764217969b6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734597147,
      "headline": "Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time",
      "id": 132050830,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1057621642/image_1057621642.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my analysis of MRK stock.",
      "url": "https://finnhub.io/api/news?id=6449b500963559f7a1006b8cb1ae53370bba70ce91ce34311c71d764217969b6"
    }
  },
  {
    "ts": null,
    "headline": "PeptiDream: Opulent Dream Now A Reality",
    "summary": "PeptiDream's PDPS platform offers a promising investment opportunity due to the new therapeutic class of macrocyclic peptide. Read my analysis of PPTDF stock.",
    "url": "https://finnhub.io/api/news?id=99543bc9e0c237e10d3cb5d2508609580e9fdcaaf90ae892cefed3b236750796",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734596763,
      "headline": "PeptiDream: Opulent Dream Now A Reality",
      "id": 132050840,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346182684/image_1346182684.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "PeptiDream's PDPS platform offers a promising investment opportunity due to the new therapeutic class of macrocyclic peptide. Read my analysis of PPTDF stock.",
      "url": "https://finnhub.io/api/news?id=99543bc9e0c237e10d3cb5d2508609580e9fdcaaf90ae892cefed3b236750796"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s RSV antibody could soon paddle into the rough waters of a crowded market",
    "summary": "A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.",
    "url": "https://finnhub.io/api/news?id=a613b84ce88b1b8e0dc13b6f79749c525cdb020c8b612d9ab747fa678e682bd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734595200,
      "headline": "Merck’s RSV antibody could soon paddle into the rough waters of a crowded market",
      "id": 132052818,
      "image": "https://imgproxy.divecdn.com/LWPxHVUcDkZMiMUsy0TWcd-p9KYWrzM3Siin1LumbOc/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjEwOTMxMjkxXzEuanBn.webp",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.",
      "url": "https://finnhub.io/api/news?id=a613b84ce88b1b8e0dc13b6f79749c525cdb020c8b612d9ab747fa678e682bd5"
    }
  },
  {
    "ts": null,
    "headline": "Merck's HIV treatment meets main goal of two late-stage studies",
    "summary": "Merck said on Thursday its experimental drug combination to treat some adults with HIV-1 infection met the main goal of two late-stage studies. ...",
    "url": "https://finnhub.io/api/news?id=95e01a74e6c1b26bc5cfb4fc3b318277d0cce7ef16e65a602454157016a1fc71",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734591539,
      "headline": "Merck's HIV treatment meets main goal of two late-stage studies",
      "id": 132049535,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck said on Thursday its experimental drug combination to treat some adults with HIV-1 infection met the main goal of two late-stage studies. ...",
      "url": "https://finnhub.io/api/news?id=95e01a74e6c1b26bc5cfb4fc3b318277d0cce7ef16e65a602454157016a1fc71"
    }
  }
]